Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  erlotinib hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 420 for your search:
Start Over
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO18109, NCT00949910
A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML20569, NCT01066884
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25478, NCT01230710
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25575, NCT01287754
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML27880, 2011-002168-26, NCT01609543
A Study of Second-Line Therapy With Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML29028, NCT02000531
TAilored Post-Surgical Therapy in Early Stage NSCLC
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: IFCT-0801, Eudract : 2008-004939-38, NCT00775385
Phase III Randomized Study of Carboplatin and Paclitaxel With or Without Erlotinib (Tarceva) in Patients With Chemotherapy Naive Stage IIIB or IV Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENENTECH-OSI2298g, MSKCC-01122, NCT00029016
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI3199g, NCT00091663
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI3364g, NCT00130728
Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: D-0410, NCT00153803
Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000453861, GERCOR-C04-2, EU-20565, GERCOR-OPTIMOX3, GERCOR-DREAM- C04-2, GERCOR-OPTIMOX3-TARCEVA, ROCHE-GERCOR-C04-2, NCT00265824
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: EORTC-55041, EUDRACT-2004-004333-34, NCT00263822
Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase: Phase III
Type: Health services research, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000457755, LLCG-TOPICAL, EU-20313, ISRCTN, Cancer Research UK (CTAAC), Roche AG Pharma, UCL Trial Sponsor reference, EudraCT number, ISRCTN77383050, NCT00275132
A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AVF3671g, NCT00257608
Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 75 to 90
Sponsor: Other
Protocol IDs: IFCT-0501, NCT00298415
IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2005.386, NCT00300586
Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000492254, NCCTG-N05C4, N05C4, NCT00362986
TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over; 18 to 70 in Italy
Sponsor: Other
Protocol IDs: TORCH, 2005-005968-90, NCT00349219
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00057, EUDRACT No. 2006-000259-16, NCT00364351
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI-774-302, 2005-001747-29, NCT00373425
Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: RC-57 crossover, NCT00440167
Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CT/06.05, NCT00440414
Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: ML 18729, NCT00442455
Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients With Mutations in the TK Domain of EGFR
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EURTAC-SLCG // GECP06/01, EudraCT:2006-003568-73, NCT00446225
Start Over